Pharma Industry, Pharma News, Indian Pharmaceutical Company News, International Pharmaceutical Company News update
Business Today
Dr Reddy's posts better than expected Q3 numbers but concerns remain

A day earlier, the company had informed the bourses that a re-inspection carried out by the German regulator at the company's formulations making plant at Bachupally, Hyderabad, had led to the EU GMP non-compliance getting withdrawn by the government of Bavaria and this means the plant could restart dispatching its approved products to the European Union.

 
 
Market opportunity for the drug is huge in the country, as about Rs 35,000 crore worth of drugs are delivered every year in oral solid dosage forms.
After capping prices of stents, concerns are that the government may now be moving towards expanding the ambit of price caps to other consumables in healthcare.
On December 7th, Mylan launched 'HepBest', which it called, "the first drug approved in eight years for management of chronic Hepatitis B infection in India." 
Advertisement